Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Who assigns value in value-based insurance design?

Joel Lexchin
CMAJ January 06, 2020 192 (1) E15; DOI: https://doi.org/10.1503/cmaj.73617
Joel Lexchin
Emergency physician, University Health Network and Faculty of Medicine, University of Toronto, Toronto, Ont.
MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Public money should not be used to pay for prescription drugs of little to no medical value. To the extent that value-based insurance design, whereby drugs of lower medical value attract a higher copay, advances this proposition, it is an idea that has merit.1 However, there are also substantial problems with value-based insurance design that should give policymakers cause for concern.

First is how to determine value. In some cases, it is easy to assign value (e.g., insulin to treat type 1 diabetes is clearly a valuable drug); however, in other instances it is more difficult. As a 71-year-old man, I place a high value on using an α-blocker because it allows me to sleep through the night without needing to get up and urinate. Where would α-blockers fit into a value-based insurance design system? If they were deemed to be of low value — after all they are certainly not life saving or even life extending — and had a high copay attached to them, then I might not be able to afford them, and my quality of life would not be as good.

More important is who is being penalized under a value-based insurance design system. Ideally, a prescription should be the result of a negotiation between the prescriber and the patient; however, most patients accept the decision of the prescriber that a particular medicine is necessary for their health. Unless we accept that patients demand a prescription for a low-value medicine and the prescriber acquiesces to that demand, it is the clinician who makes the decision about what drug to prescribe. But if that is a drug that is low value and has a high copay, it is the patient who has to pay the copay (i.e., the patient is penalized for the decision of the clinician). If we want to “steer” anyone away from low-value drugs, as Drs. Yeung and Morgan1 discussed in their CMAJ Analysis article, then it should be the people who write the prescriptions not the people who will be taking them who should be affected. Perhaps it should be the clinicians who are responsible for the copay, not the patients.

Footnotes

  • Competing interests: In 2016–2019, Joel Lexchin was a paid consultant on 2 projects: one looking at developing principles for conservative diagnosis (Gordon and Betty Moore Foundation) and a second deciding what drugs should be provided free of charge by family physicians (Government of Canada, Ontario Supporting Patient Oriented Research Support Unit and the St. Michael’s Hospital Foundation). He also received payment for being on a panel at the American Diabetes Association, for a talk at the Toronto Reference Library, for writing a brief in an action for adverse effects of a drug for Michael F. Smith (lawyer) and from the Canadian Institutes of Health Research (CIHR) for presenting at a workshop on conflict of interest in clinical practice guidelines. He is currently a member of research groups that are receiving money from CIHR and the National Health and Medical Research Council of Australia. He is a member of the Foundation Board of Health Action International and the board of Canadian Doctors for Medicare. He receives royalties from University of Toronto Press and James Lorimer & Co. Ltd. for books he has written.

Reference

  1. ↵
    1. Yeung K,
    2. Morgan SG
    . Should national pharmacare apply a value-based insurance design? CMAJ 2019;191:E811–5.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (1)
CMAJ
Vol. 192, Issue 1
6 Jan 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Who assigns value in value-based insurance design?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Who assigns value in value-based insurance design?
Joel Lexchin
CMAJ Jan 2020, 192 (1) E15; DOI: 10.1503/cmaj.73617

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Who assigns value in value-based insurance design?
Joel Lexchin
CMAJ Jan 2020, 192 (1) E15; DOI: 10.1503/cmaj.73617
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • Reference
  • Responses
  • Metrics
  • PDF

Related Articles

  • Should national pharmacare apply a value-based insurance design?
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
  • Vigilance needed with methamphetamine-associated psychosis
  • Critical examination of incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire